UPC News

Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Universe Pharmaceuticals INC. ("Universe Pharmaceuticals" or the "Company") (NASDAQ: UPC) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A UNIVERSE...

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Universe Pharmaceuticals INC. ("Universe Pharmaceuticals" or the "Company") (NASDAQ: UPC) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A UNIVERSE...

Universe Pharmaceuticals Shares jumped after hours as eight investors disclosed ownership stakes following the company's patent acquisition.read more...

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding (NASDAQ:SLBT)read more...

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus Pharmaceuticalsread more...

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock rose 11.63%read more...

Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ:UPC)read more...

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday's regular session. The company's market cap stands at $1.9 million. Decoy Therapeutics (NASDAQ:DCOY) sharesread more...

Universe Pharmaceuticals (NASDAQ:UPC) announced that it has entered into a share purchase agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The proposed acquisition, valued at approximately US$10.75 million and payable in Class A ordinary shares, is expected to broaden the company's research and development platform while expanding its focus beyond its existing traditional Chinese medicine business.